John F. Neylan - 20 Sep 2021 Form 4 Insider Report for Angion Biomedica Corp. (ELTX)

Role: Senior Vice President and Chief Medical Officer
Signature: /s/ Jennifer J. Rhodes, as attorney-in fact for John F. Neylan
Issuer symbol: ELTX
Transactions as of: 20 Sep 2021
Net transactions value: -$3,786
Form type: 4
Filing time: 21 Sep 2021, 16:32:03 UTC
Previous filing: 19 Aug 2021
Next filing: 20 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELTX	Common Stock	Sale	$3,786	-376	-1%	$10.07	36,241	20 Sep 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.07 to $10.09 inclusive.

Remarks:

Senior Vice President and Chief Medical Officer